Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 3 · 42.9%High 3 · 42.9%

Umeclidinium bromide vs placebo

Exacerbations requiring steroids or antibiotics or both: number of participants · patients with chronic obstructive pulmonary disease

Umeclidinium bromide leads to lower number of participants with exacerbations requiring steroids,… compared with placebo (high certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 0.61 [0.46, 0.8]
4 studies · 1922 participants
High

Umeclidinium bromide vs placebo

Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with chronic obstructive pulmonary disease

Umeclidinium bromide probably leads to higher quality of life: number of participants with ≥ 4 units improvement… compared with placebo (moderate certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 1.45 [1.16, 1.82]
3 studies · 1397 participants
Moderate

Umeclidinium bromide vs placebo

Non‐fatal serious adverse events · patients with chronic obstructive pulmonary disease

Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 1.33 [0.89, 2]
4 studies · 1922 participants
Moderate

Umeclidinium bromide vs placebo

Hospitalisations due to COPD exacerbations · patients with chronic obstructive pulmonary disease

Umeclidinium bromide showed no clear difference in number of participants with hospital admissions due to COPD… compared with placebo (low certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 0.86 [0.25, 2.92]
4 studies · 1922 participants
Low

Umeclidinium bromide vs placebo

Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · patients with chronic obstructive pulmonary disease

Umeclidinium bromide leads to higher number of participants with ≥ 1 unit improvement in TDI focal score compared with placebo (high certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 1.71 [1.37, 2.15]
3 studies · 1441 participants
High

Umeclidinium bromide vs placebo

Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1381 participants
High

Umeclidinium bromide vs placebo

Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease

Umeclidinium bromide showed no clear difference in adverse events (not including serious adverse events) compared with placebo (moderate certainty).

1 finding from 1 review

Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) 2017 · Cochrane Headline outcomes only
OR 1.06 [0.85, 1.31]
4 studies · 1922 participants
Moderate